Stephen OHara, chief executive of OptiBiotix

OptiBiotix explores dual listing in America

Life sciences firm OptiBiotix Health, which develops compounds to tackle obesity, cardiovascular disease and diabetes, has extended its geographic reach into 24 new countries and is exploring the potential of a dual NASDAQ listing.

Alastair Smith, CEO, Avacta Group

Avacta shares jump on Korean venture

Drug developer Avacta, which is working on cures for lung, breast, gastric and bowel cancer, has formed a new joint venture with a leading South Korean pharma company to develop the next generation of cell and gene therapies.

Load more
Get daily updates Sign Up X